ReviewFrontiers in nutrition2025
The impact of diet and gut microbiota on development, treatment, and prognosis in prostate cancer.
Review in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Microbial Genomic Consortia in Prostate Cancer: Mechanistic Signaling, the Gut-Prostate Axis, and Translational Perspectives.Cancers · 2026Review
- Exposure to 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine causes cecal microbiota dysbiosis in mice.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) progression is driven by a complex interplay of factors, including genetics, lifestyle, and environmental influences. Diet and gut microbiota have emerged as pivotal cancer development and treatment response modulators. This review delves into the intricate relationship between dietary modifications and gut microbiota, and their combined impact on PCa progression. Diets abundant in plant-based foods, fiber, and prebiotics promote beneficial gut microbiota profiles that support anti-inflammatory and anti-carcinogenic processes. In contrast, the Western dietary pattern, characterized by high levels of saturated fats and processed foods, may lead to dysbiosis, fostering pro-inflammatory conditions and the production of metabolites that enhance tumorigenesis. The gut microbiota influences the behavior of PCa through immune modulation, metabolic by-products, and interactions with systemic therapies. Emerging evidence, primarily derived from preclinical models or studies in non-PCa contexts, suggests that diet and gut microbiota may influence the development and progression of PCa. However, further PCa-specific clinical research is needed to validate these associations. Future research should prioritize the development of precise dietary recommendations and microbiota-targeted therapies that can be seamlessly incorporated into clinical practice for more personalized and effective cancer care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.